Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

J. Mlcochova, P. Faltejskova-Vychytilova, M. Ferracin, B. Zagatti, L. Radova, M. Svoboda, R. Nemecek, S. John, I. Kiss, R. Vyzula, M. Negrini, O. Slaby,

. 2015 ; 6 (36) : 38695-38704.

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000929

Grant support
NT13860 MZ0 CEP Register

The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patients with mCRC (2006-2009) was included and further divided into exploratory and validation cohorts. MiRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 28 patients of wt-RAS mCRC treated with cetuximab and 24 patients of wt-RAS mCRC treated with panitumumab. We identified 9 miRNAs with significantly different expression between responders and non-responders to cetuximab therapy (P ≤ 0.01). These 9 miRNAs were further evaluated in two independent cohorts of patients and miR-31-3p (P < 0.001) and miR-31-5p (P < 0.001) were successfully confirmed as strongly associated with TTP in wt-RAS mCRC patients treated with cetuximab but not panitumumab. When evaluated on the complete cohort of cetuximab patients (N = 69), miR-31-3p (HR, 5.10; 95% CI, 2.52-10.32; P < 0.001) and miR-31-5p (HR, 4.80; 95% CI, 2.50-9.24; P < 0.001) were correlated with TTP on the comparable level of significance. There was no difference in miR-31-5p/3p expression levels in RAS mutated and wild-type tumor samples. MiR-31-5p/3p are promising predictive biomarkers of cetuximab response in wt-RAS mCRC patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000929
003      
CZ-PrNML
005      
20191029133446.0
007      
ta
008      
170103s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.5735 $2 doi
024    7_
$a 10.18632/oncotarget.5735 $2 doi
035    __
$a (PubMed)26497852
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mlčochová, Jitka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. $7 _AN065407
245    10
$a MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab / $c J. Mlcochova, P. Faltejskova-Vychytilova, M. Ferracin, B. Zagatti, L. Radova, M. Svoboda, R. Nemecek, S. John, I. Kiss, R. Vyzula, M. Negrini, O. Slaby,
520    9_
$a The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patients with mCRC (2006-2009) was included and further divided into exploratory and validation cohorts. MiRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 28 patients of wt-RAS mCRC treated with cetuximab and 24 patients of wt-RAS mCRC treated with panitumumab. We identified 9 miRNAs with significantly different expression between responders and non-responders to cetuximab therapy (P ≤ 0.01). These 9 miRNAs were further evaluated in two independent cohorts of patients and miR-31-3p (P < 0.001) and miR-31-5p (P < 0.001) were successfully confirmed as strongly associated with TTP in wt-RAS mCRC patients treated with cetuximab but not panitumumab. When evaluated on the complete cohort of cetuximab patients (N = 69), miR-31-3p (HR, 5.10; 95% CI, 2.52-10.32; P < 0.001) and miR-31-5p (HR, 4.80; 95% CI, 2.50-9.24; P < 0.001) were correlated with TTP on the comparable level of significance. There was no difference in miR-31-5p/3p expression levels in RAS mutated and wild-type tumor samples. MiR-31-5p/3p are promising predictive biomarkers of cetuximab response in wt-RAS mCRC patients.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a protinádorové látky $x aplikace a dávkování $x terapeutické užití $7 D000970
650    _2
$a cetuximab $x terapeutické užití $7 D000068818
650    _2
$a kohortové studie $7 D015331
650    _2
$a kolorektální nádory $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HCT116 buňky $7 D045325
650    _2
$a buňky HT-29 $7 D019073
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x biosyntéza $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a erbB receptory $x antagonisté a inhibitory $7 D066246
650    _2
$a ras proteiny $x genetika $7 D018631
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vychytilová, Petra, $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, Brno, Czech Republic. $d 1987- $7 xx0165184
700    1_
$a Ferracin, Manuela $u Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
700    1_
$a Zagatti, Barbara $u Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
700    1_
$a Radova, Lenka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
700    1_
$a Svoboda, Marek, $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, Brno, Czech Republic. $d 1975- $7 xx0098478
700    1_
$a Němeček, Radim $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, Brno, Czech Republic. $7 xx0128809
700    1_
$a John, Stanislav, $u Department of Oncology and Radiotherapy, Faculty Hospital Hradec Kralove, Hradec Kralove, Czech Republic. $d 1984- $7 xx0234939
700    1_
$a Kiss, Igor, $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, Brno, Czech Republic. $d 1965- $7 xx0031864
700    1_
$a Vyzula, Rostislav, $u Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, Brno, Czech Republic. $d 1952- $7 nlk20000083661
700    1_
$a Negrini, Massimo $u Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
700    1_
$a Slabý, Ondřej, $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Masaryk Memorial Cancer Institute, Department of Comprehensive Cancer Care, Masaryk University, Faculty of Medicine, Brno, Czech Republic. $d 1981- $7 js20030220015
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 6, č. 36 (2015), s. 38695-38704
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26497852 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20191029133925 $b ABA008
999    __
$a ok $b bmc $g 1180069 $s 961496
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 6 $c 36 $d 38695-38704 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
GRA    __
$a NT13860 $p MZ0
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options